<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0"><gtr:id>B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0</gtr:id><gtr:name>Nemaura Pharma Limited</gtr:name><gtr:address><gtr:line1>Loughborough Innovation Centre
Charnwood Building
Ashby Road</gtr:line1><gtr:city>Loughborough</gtr:city><gtr:postCode>LE11 3AQ</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0</gtr:id><gtr:name>Nemaura Pharma Limited</gtr:name><gtr:address><gtr:line1>Loughborough Innovation Centre
Charnwood Building
Ashby Road</gtr:line1><gtr:city>Loughborough</gtr:city><gtr:postCode>LE11 3AQ</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>177939.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AB7E1A3E-BCA4-4E0D-AA72-6750265F4878"><gtr:id>AB7E1A3E-BCA4-4E0D-AA72-6750265F4878</gtr:id><gtr:firstName>Kathryn</gtr:firstName><gtr:surname>Farrar</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710437"><gtr:id>2F41F561-4C0E-4593-B08C-3B60C19949FB</gtr:id><gtr:title>Micro Needle</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710437</gtr:grantReference><gtr:abstractText>Nemaura
Pharma has developed a number of drug delivery systems focusing on delivery of
drugs through the skin. We wish to undertake a proof of concept to deliver the Tdap vaccine
(Tetanus, Diphtheria and Pertussis) using a solid micro-dose injector.
The Tdap booster vaccine must be adminsitered several times over a persons life span, and
also to pregnant women during the third trimester. Pertussis alone is a highly contagious
bacterial disease caused by Bordetella pertussis and affects 48.5 million people worldwide
yearly, resulting in nearly 295,000 deaths. In April and May 2012, pertussis was declared to
be at epidemic levels in the US state of Washington. In September 2012, a similar epidemic of
pertussis was seen in parts of the United Kingdom, with several babies dying as a result.
The Tdap vaccine is currently administered by needle injection to children and adults and
requires refrigeration; it is completely ineffective if stored at room temperature for more than
8 hours. The vaccine also causes serious adverse skin reactions in more than 1 in 10 people.
Nemaura?s device is disposable, designed to deliver a solid dose that can therefore deliver the
vaccine at a fraction of the volume required for a liquid injection, thus significantly
minimising skin trauma and adverse events, and the solid nature of the dosage form allows
enahnced stability at room and elevated temperatures without the need for refrigeration. This
method of delivery has also been independently reported to have a dose sparing effect, leading
to comparable efficacy at a reduced dose. These factors have the potential to collectively
transform the delivery of the Tdap vaccine and numerous other vaccines.</gtr:abstractText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710437</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>